

5. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *N Engl J Med.* 1981;304:801-7.
6. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. *Lancet.* 1981;2:823-7.
7. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *JAMA.* 1982 Mar 26;247(12):1707-14 doi: 10.1001/jama.1982.03320370021023.
8. Kršíak M. Zkrácený text přednášky v Kurzu farmaceutické medicíny 25.3.2006. Sborník časopisu Farmakoterapie, 1. díl, říjen 2006, str. 7-12.
9. Harris AS, Estandia A, Tillotson RF. Ventricular ectopic rhythms and ventricular fibrillation following cardiac sympathectomy and coronary occlusion. *Am J Physiol.* 1951 Jun;165(3):505-12. doi: 10.1152/ajplegacy.1951.165.3.505. PMID: 14846969.
10. Vrána M, Blazek Z, Fejfar Z, Netušil M, Trcka V. Prevention of ventricular fibrillation in experimental myocardial infarction. *Cor Vasa.* 1977;19(3):243-5. PMID: 923260.
11. Vrána M, Fejfar Z, Netušil M, Blazek Z, Trcka V. Stimulation threshold studies and the effect of antiarrhythmic drugs. *Basic Res Cardiol.* 1978 Nov-Dec;73(6):618-26. doi: 10.1007/BF01906799. PMID: 34384.
12. Waagstein F, Rutherford JD. The Evolution of the Use of  $\beta$ -Blockers to Treat Heart Failure: A Conversation With Finn Waagstein, MD. *Circulation.* 2017 Sep 5;136(10):889-893. doi: 10.1161/CIRCULATIONAHA.117.029934. PMID: 28874420.
13. Leung KL, Fong W, Freedman B, et al. Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis. *Hong Kong Med J.* 2020 Feb;26(1):27-34. doi: 10.12809/hkmj198077. Epub 2020 Jan 22. Erratum in: *Hong Kong Med J.* 2020 Apr 17;26(2):155. doi: 10.12809/hkmj198077-c. PMID: 32051330.
14. Coats AJS. Beta-blockers, hypertension, and weight gain: the farmer, the chicken, and the egg. *Hong Kong Med J.* 2020 Feb;26(1):6-7. doi: 10.12809/hkmj205093. PMID: 32077860.
15. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. *Hypertension.* 2001 Feb;37(2):250-4. doi: 10.1161/01.hyp.37.2.250. PMID: 11230280 Review.
16. Boxall BW, Clark AL. Beta-blockers and weight change in patients with chronic heart failure. *J Card Fail.* 2012 Mar;18(3):233-7. doi: 10.1016/j.cardfail.2011.10.016. Epub 2011 Dec 3. PMID: 22385944
17. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. *Obes Rev.* 2001 Nov;2(4):275-80. doi: 10.1046/j.1467-789x.2001.00044.x. PMID: 12119998 Review.
18. Anekwe CV, Ahn YJ, Bajaj SS, et al. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: A review. *Ann N Y Acad Sci.* 2024 Mar;1533(1):145-155. doi: 10.1111/nyas.15112. Epub 2024 Feb 22. PMID: 38385953 Review.
19. DiNicolantonio JJ, Fares H, Niazi AK, et al. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart.* 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015. PMID: 25821584 Free PMC article. Review.
20. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. *Drug Saf.* 2015 Dec;38(12):1153-68. doi: 10.1007/s40264-015-0339-z. PMID: 26370106.
21. DiNicolantonio JJ, Fares H, Niazi AK, et al. Open Heart 2015;2:e000230. doi:10.1136/openhrt-2014-000230.
22. Palau P, de la Espriella R, Seller J, et al.  $\beta$ -Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction. *JAMA Cardiol.* 2024 Apr 1;9(4):392-396. doi: 10.1001/jamacardio.2023.5500. PMID: 38324280; PMCID: PMC10851133.
23. Bangalore S, Makani H, Radford M et al. Clinical outcomes with  $\beta$ -blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med.* 2014;127:939-95.
24. Vitovec J, Špinar J, Špinarová L. Betablokátory po infarktu myokardu a u chronické ICHS. *Vnitř Lék.* 2022;68(3):178-180.
25. Yndigezn T, Lindahl B, Mars K, et al; REDUCE-AMI Investigators. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. *N Engl J Med.* 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. PMID: 38587241.
26. Silvain J, Cayla G, Ferrari E, et al; ABYSS Investigators of the ACTION Study Group. Beta-Blocker Interruption or Continuation after Myocardial Infarction. *N Engl J Med.* 2024 Oct 10;391(14):1277-1286. doi: 10.1056/NEJMoa2404204. Epub 2024 Aug 30. PMID: 39213187.
27. O'Donoghue ML, Montalescot G. What Now For Beta-Blockers Post-Mi? Reconciling REDUCE-AMI and ABYSS. *Medscape* September 04, 2024. <https://www.medscape.com/viewarticle/what-now-beta-blockers-post-mi-reconciling-reduce-ami-and-2024a1000fz1?form=fpf>.

